Allergy Immunotherapy Success Rate: SCIT vs SLIT Evidence by Allergen
Allergy immunotherapy achieves meaningful, lasting symptom control across both injection (SCIT) and sublingual (SLIT) modalities. SCIT produces a pooled symptom reduction of SMD −0.73 versus placebo across 51 randomized trials, while SLIT grass tablets deliver roughly 30% symptom reduction. Lee et al. 2018 found 76.6% cumulative remission at a median 4.9 years of HDM treatment. Lasting benefit requires at least 3 years of treatment for either route.
10 peer-reviewed sources
Immunotherapy reduces allergy symptoms by roughly one-third on average, with 76.6% of HDM patients achieving remission at 5 years. Grass and dust-mite allergens show the strongest evidence; benefit requires at least 3 years of treatment.
How Effective Is Allergy Immunotherapy Overall?
Allergy immunotherapy is the only treatment that targets the underlying immune dysfunction driving allergic disease, not just the symptoms. Across more than 100 randomized controlled trials and multiple Cochrane systematic reviews, subcutaneous immunotherapy (SCIT, allergy shots) reduces allergic rhinitis symptom scores by a pooled standardized mean difference of −0.73 versus placebo — roughly a one-third reduction in symptom severity — while also cutting rescue medication use by SMD −0.57. Sublingual immunotherapy (SLIT) produces somewhat smaller average effects in placebo-controlled analyses but delivers comparable results to SCIT in direct head-to-head trials, with a dramatically better safety profile.
The headline number most patients want to know is the responder rate. Observational cohorts suggest that 50–80% of treated patients achieve clinically meaningful improvement, depending on allergen type, treatment duration, and how strictly 'responder' is defined. In a real-world Curex study of 2,897 patients on at-home sublingual immunotherapy (Tharpe et al., Frontiers in Allergy, 2026, peer-reviewed), clinically meaningful symptom improvement rose to 45% of patients by two years, quality-of-life improvement reached 90.7%, adherence was over 90%, and no anaphylaxis was reported. The critical variable is duration: treatment courses shorter than 3 years produce limited post-treatment benefit, while courses of 3–5 years achieve remission that can last 7–12 years after stopping.
Before any immunotherapy can begin, identifying exactly which allergens are driving your symptoms is essential — this determines whether the evidence is strong for your specific triggers. At-home allergy test kits like those from Curex cover 40+ common allergens and return results within about a week, making that first diagnostic step easier to complete.
Immunotherapy is the only disease-modifying treatment for allergic rhinitis and asthma, with benefit persisting years after the course ends — but only after a minimum of 3 years of treatment.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Success Rates by Allergen Type: Where the Evidence Is Strongest
Immunotherapy success rates vary substantially by allergen type. Grass pollen and dust mites represent the best-supported indications, with the largest, most consistent randomized trial bases. Ragweed occupies a solid middle tier for rhinitis. Cat allergen shows moderate evidence for SCIT. Dog, cockroach, and multi-mold allergens have weak or insufficient evidence — a critical distinction that directly affects whether immunotherapy is likely to work for a given patient. The Calderon Cochrane review (2007, 51 RCTs, 2,871 patients) is the landmark SCIT efficacy dataset for seasonal allergic rhinitis: pooled symptom SMD −0.73 and medication SMD −0.57. For comparison, the Radulovic Cochrane SLIT review (2010, 60 RCTs, 4,589 patients) found symptom SMD −0.49 and medication SMD −0.32. These confidence intervals overlap, and Nelson's 2015 network meta-analysis found no significant efficacy difference between SCIT and SLIT-tablets for grass pollen specifically — symptom SMD difference of 0.01. For HDM allergen specifically, Lee et al. (2018, n=304) demonstrated 76.6% cumulative clinical remission at a median 4.9 years of SCIT, with treatment duration of at least 3 years carrying an odds ratio of 7.37 for sustained remission.
Success Rate by Duration
Curious how at-home immunotherapy compares for you?
Take the free eligibility quiz to see your at-home allergy shots options with Curex.
See if you qualifyCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
SCIT vs SLIT vs Medications: Head-to-Head Outcomes
Choosing between allergy shots (SCIT) and sublingual immunotherapy (SLIT) should be guided by allergen type, patient lifestyle, and how the evidence base compares for your specific triggers. For FDA-approved single-allergen indications — timothy grass, 5-grass, ragweed, and house dust mite — SLIT-tablets achieve comparable symptom reduction to SCIT with a dramatically lower risk of systemic reactions. For patients who are polysensitized and need custom multi-allergen mixes, SCIT retains a clinical advantage because FDA-approved tablets treat only one allergen each — and SCIT can now be done at home through Curex, removing the weekly clinic trip that was its main drawback. Antihistamines and nasal corticosteroids control symptoms well but provide no disease modification — they do not reduce sensitization, prevent new allergies, or lower long-term asthma risk. Immunotherapy's unique value is that it can restructure the immune response itself, with benefits that persist years after treatment ends.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT) — CurexBest | Symptom SMD −0.73; 76.6% HDM remission at 5 years; strongest for grass, dust mite, ragweed | 3–5 years total (6 months buildup, then ongoing maintenance) | $3,000–$20,000 depending on insurance | Self-administered at home with Curex: weekly build-up for 6 months, on an individualized schedule thereafter; the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, with a brief self-observation after each | Systemic reactions in 0.1% of injections; ~1 fatality per 2.5 million injections historically; at home with Curex, a USP <797> sterile-compounded serum, a prescribed epinephrine auto-injector confirmed on hand, and Virtual Shot Room–supervised first and dose-change injections keep it safe for eligible patients |
SLIT Tablets (FDA-Approved) | ~30% symptom reduction for grass; 17% TCRS reduction for HDM; comparable to SCIT in direct trials | 3–5 years; first dose in clinic, then daily at home | $1,200–$5,300/year per tablet; treats only one allergen | Daily at-home dosing after first supervised dose; no clinic trips or needles | Zero confirmed fatalities worldwide; anaphylaxis in 0.02% of patients in pooled trials |
SLIT Drops (Sublingual) | Comparable mechanism to tablets; multi-allergen coverage possible; real-world responder data accumulating | 3–5 years; daily at-home administration | $1,400–$3,600 at telehealth prices vs $15,000+ for SCIT cash | Daily at-home dosing; no needles; no clinic wait periods | No confirmed fatalities; favorable local-reaction profile similar to tablets |
Antihistamines / Nasal Steroids | Good symptom control during active use; no disease modification or lasting benefit after stopping | Ongoing — symptoms return when medication stops | $300–$1,500 OTC/Rx | Daily pills or sprays; no clinic visits needed | Excellent local safety; sedation risk with older antihistamines; no anaphylaxis risk |
- Efficacy
- Symptom SMD −0.73; 76.6% HDM remission at 5 years; strongest for grass, dust mite, ragweed
- Duration
- 3–5 years total (6 months buildup, then ongoing maintenance)
- Cost (5yr)
- $3,000–$20,000 depending on insurance
- Convenience
- Self-administered at home with Curex: weekly build-up for 6 months, on an individualized schedule thereafter; the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, with a brief self-observation after each
- Safety
- Systemic reactions in 0.1% of injections; ~1 fatality per 2.5 million injections historically; at home with Curex, a USP <797> sterile-compounded serum, a prescribed epinephrine auto-injector confirmed on hand, and Virtual Shot Room–supervised first and dose-change injections keep it safe for eligible patients
- Efficacy
- ~30% symptom reduction for grass; 17% TCRS reduction for HDM; comparable to SCIT in direct trials
- Duration
- 3–5 years; first dose in clinic, then daily at home
- Cost (5yr)
- $1,200–$5,300/year per tablet; treats only one allergen
- Convenience
- Daily at-home dosing after first supervised dose; no clinic trips or needles
- Safety
- Zero confirmed fatalities worldwide; anaphylaxis in 0.02% of patients in pooled trials
- Efficacy
- Comparable mechanism to tablets; multi-allergen coverage possible; real-world responder data accumulating
- Duration
- 3–5 years; daily at-home administration
- Cost (5yr)
- $1,400–$3,600 at telehealth prices vs $15,000+ for SCIT cash
- Convenience
- Daily at-home dosing; no needles; no clinic wait periods
- Safety
- No confirmed fatalities; favorable local-reaction profile similar to tablets
- Efficacy
- Good symptom control during active use; no disease modification or lasting benefit after stopping
- Duration
- Ongoing — symptoms return when medication stops
- Cost (5yr)
- $300–$1,500 OTC/Rx
- Convenience
- Daily pills or sprays; no clinic visits needed
- Safety
- Excellent local safety; sedation risk with older antihistamines; no anaphylaxis risk
For patients whose allergy testing confirms high-evidence triggers like grass pollen or house dust mite, Curex offers the at-home allergy shot kit (SCIT) with pricing confirmed in a current program quote — the same injected immunotherapy behind these success rates, with a USP <797> sterile-compounded serum, one weekly shot you give yourself at home, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff after a prescribed epinephrine auto-injector is confirmed on hand — no weekly clinic visits.
Join the waitlistFrequently asked questions
Is Curex approved by the FDA?
Curex's at-home allergy shots use custom-compounded extracts prescribed off-label by a clinician, which is standard practice for personalized allergen immunotherapy and is not the same as an FDA-cleared finished drug product. Separately, a few single-allergen sublingual tablets do carry FDA approval, but that is a different format that treats only one allergen at a time. Ask your allergist about the evidence behind your specific extract.
Does allergy immunotherapy actually work?
Yes, for most patients who complete a full course. Multiple randomized controlled trials and Cochrane reviews show meaningful, measurable reductions in symptom and medication scores for SCIT and SLIT versus placebo, particularly for grass pollen and dust mite. Benefit typically builds over the first 3–6 months and can persist for years after a complete 3–5-year course ends. Results vary by allergen type, so ask your allergist how the evidence applies to your specific triggers.
What is the overall success rate of allergy immunotherapy?
Allergy immunotherapy produces clinically meaningful symptom improvement in roughly half to four-fifths of treated patients in published trials, with the exact rate depending on allergen type, treatment duration, and the definition used for improvement. The Calderon Cochrane review (2007, 51 RCTs) found a pooled standardized mean difference of −0.73 for symptom scores with SCIT versus placebo — roughly a one-third reduction. For house dust mite specifically, Lee et al. (2018, n=304) reported high cumulative clinical remission at a median 4.9 years. Grass pollen and dust mite show the strongest evidence; cockroach and dog show weak evidence. Completing at least 3 years of treatment is the single strongest predictor of lasting benefit.
Is allergy immunotherapy more effective than antihistamines?
For long-term disease modification, immunotherapy is substantially more effective than antihistamines, though in head-to-head direct comparisons for short-term symptom control, intranasal corticosteroids perform similarly. Matricardi et al. (2011) calculated that SCIT produced a 34.7% relative reduction in nasal symptom scores, compared to 31.7% for mometasone and only 12.0% for desloratadine. The unique advantage of immunotherapy is not just its comparable symptom control, but the fact that benefits persist for years after treatment ends — something antihistamines and steroids cannot provide. Immunotherapy also reduces the risk of developing asthma in children with allergic rhinitis, an effect that antihistamines do not demonstrate.
How long does allergy immunotherapy take to work?
Most patients notice meaningful symptom improvement within 3 to 6 months of starting immunotherapy — often around the time they reach or approach their maintenance dose. The AAAAI/ACAAI Practice Parameter states that clinical improvement is usually observed within one year of reaching the maintenance dose (Cox et al., JACI 2011). Some patients experience earlier benefit during the buildup phase, while others require closer to 12 months. If no benefit is evident after one full year of maintenance, your allergist will reassess allergen selection, dosing, and whether to continue treatment. For lasting benefit that persists after stopping, at least 3 years of treatment is required per EAACI 2018 guidelines.
Does allergy immunotherapy success depend on the allergen type?
Yes, allergen type is one of the most important predictors of immunotherapy success. Grass pollen SCIT has the largest and most consistent randomized trial base, with Di Bona et al. (2012) reporting a symptom SMD of −0.92. Dust mite SCIT shows strong evidence with a symptom SMD of −0.95 in the Calderon Cochrane review (2010). Cat allergen demonstrates moderate evidence with meaningful symptom reduction in controlled chamber studies. At the other end, dog dander has weaker evidence due to extract standardization problems, and cockroach SCIT failed its primary endpoint in the CRITICAL trial (Zoratti et al., JACI 2024). Your allergist uses this allergen-specific evidence to counsel whether immunotherapy is likely to work for your specific triggers before recommending it.
How long do allergy shot benefits last after stopping?
Benefits from a complete 3–5-year immunotherapy course typically persist for several years after stopping — and in some cases much longer. Durham et al. (N Engl J Med, 1999) demonstrated that 3–4 years of grass SCIT produced sustained symptom control for at least 3 years post-treatment, with no meaningful difference between patients who continued maintenance and those who stopped. The longest follow-up data come from Eng et al. (Allergy, 2006), who found significant clinical benefit 12 years after childhood grass SCIT. The EAACI recommends a minimum of 3 years for post-treatment durability.
Is SCIT or SLIT more effective for allergy treatment?
For the most-studied allergens, SCIT and SLIT-tablets achieve broadly comparable efficacy. Nelson's 2015 network meta-analysis — the most rigorous direct comparison for grass pollen — found no statistically significant difference between SCIT and SLIT-tablets. Some indirect analyses favor SCIT slightly, while others find equivalence. Head-to-head randomized trials are small and have not shown statistically significant differences. The decisive distinction is safety: SCIT carries a higher estimated rate of rare fatal reactions than SLIT, where no fatality has ever been documented. For polysensitized patients needing custom multi-allergen treatment, SCIT holds a practical advantage because FDA-approved tablets each treat only one allergen.
What percentage of patients complete allergy immunotherapy?
Real-world completion rates are substantially lower than those observed in clinical trials. The largest adherence study — Kiel et al. (JACI 2013, n=6,486 Dutch patients) — found that a minority of SCIT users and an even smaller share of SLIT users completed the minimum 3-year course, with median treatment durations of 1.7 years for SCIT and 0.6 years for SLIT. US data are similarly sobering: Hankin et al. (JACI 2008) reported that most pediatric Medicaid patients failed to complete 3 years, and over half stopped within the first year. Adherence is the dominant practical limitation on immunotherapy effectiveness in real-world settings.
Can allergy immunotherapy prevent asthma in children?
Evidence from multiple long-term studies suggests immunotherapy reduces the risk of developing asthma in children with allergic rhinitis, though a definitive randomized controlled trial with asthma diagnosis as the primary endpoint has not been completed for SCIT. The PAT study (Möller et al., JACI 2002; n=205 children with grass/birch rhinitis) found significantly fewer asthma cases in the SCIT group, and the 10-year follow-up (Jacobsen et al., Allergy 2007) confirmed the benefit persisted 7 years after stopping treatment. This asthma-prevention evidence is stronger for SCIT than for SLIT, where the GAP trial (Valovirta et al., 2018) failed its primary asthma-diagnosis endpoint.
What factors predict success with allergy immunotherapy?
Several clinical factors are associated with better immunotherapy outcomes, based on observational cohort data. Lee et al. (2018) identified treatment duration of at least 3 years, higher baseline specific IgE, and milder baseline disease as the strongest predictors for HDM SCIT. Monosensitization — having one main allergen trigger rather than multiple — is associated with more durable post-treatment benefit than polysensitization. Younger age at treatment start and shorter disease duration before starting are also positive predictors. From the allergen side, grass pollen and dust mite confer the highest response likelihood; cockroach and non-Alternaria mold the lowest. Reaching the full therapeutic maintenance dose is essential.
Related Articles
Immunotherapy for Allergy: All Modalities Compared | Curex
Allergy immunotherapy: SCIT shots, SLIT drops and tablets, and emerging options compared. Efficacy, safety, cost, and convenience data to choose your path.
Read moreAre Allergy Shots Subcutaneous? Injection Depth | Curex
Allergy shots are subcutaneous — injected into fat beneath the skin, not muscle. Learn why injection depth matters for immune tolerance and safety in SCIT.
Read moreImmunotherapy Allergy Shots Near Me: Find a Provider | Curex
82% of US counties have no allergist. Use ABAI/AAAAI directories to find local SCIT — or get the at-home allergy shot kit from Curex without traveling.
Read moreAre Allergy Shots Subcutaneous or Intramuscular? | Curex
Allergy shots are always subcutaneous, never intramuscular. Learn the clinical reasons why IM is avoided and what systemic reaction risks it would carry.
Read moreImmunotherapy for Allergy: How It Rewires Immunity | Curex
Immunotherapy for allergy reprograms immunity via FOXP3+ Tregs and IgG4 blocking antibodies. Learn how the immune cascade leads to lasting allergy relief.
Read moreAllergy Shots as Immunotherapy: Complete Evidence | Curex
Allergy shots are real immunotherapy: 51 RCTs with disease-modifying benefits lasting years. The original immune therapy, predating cancer IT by 100 years.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.